Profile
Jonathan Polak is currently the Chief Executive Officer & Director at Mesentech, Inc.
Jonathan Polak active positions
| Companies | Position | Start |
|---|---|---|
Mesentech, Inc.
 Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada. | Chief Executive Officer | 2018-05-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Mesentech, Inc.
Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada. | Health Technology |
- Stock Market
- Insiders
- Jonathan Polak
